Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses developing anti-fibrotic and anti-inflammatory therapies to treat cardiovascular disease. Its lead product is CardiolRx, which reduces cardiovascular and respiratory events in patients hospitalized with COVID-19. The company is also developing a subcutaneous formulation of CardiolRx to treat fibrosis and inflammation that progress to heart failure. Cardiol Therapeutics was incorporated in 2017 and is headquartered in Oakville, Ontario, Canada.
Name / Ticker | Price | Zen Rating |
---|---|---|
$39.11 | A | |
$16.42 | A | |
$25.77 | A |